414 related articles for article (PubMed ID: 19374595)
1. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
Prescrire Int; 2009 Aug; 18(102):145-7. PubMed ID: 19739343
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Barlési F; Tchouhadjian C; Doddoli C; Villani P; Greillier L; Kleisbauer JP; Thomas P; Astoul P
Fundam Clin Pharmacol; 2005 Jun; 19(3):385-93. PubMed ID: 15910663
[TBL] [Abstract][Full Text] [Related]
7. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib for non-small-cell lung cancer treatment.
D'Incecco A; Cappuzzo F
Expert Opin Drug Saf; 2011 Nov; 10(6):987-96. PubMed ID: 21905963
[TBL] [Abstract][Full Text] [Related]
9. Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Farina G; Longo F; Martelli O; Pavese I; Mancuso A; Moscetti L; Labianca R; Bertolini A; Cortesi E; Farris A; Fagnani D; Locatelli MC; Valmadre G; Ardizzoia A; Tomirotti M; Rulli E; Garassino MC; Scanni A
Clin Lung Cancer; 2011 Mar; 12(2):138-41. PubMed ID: 21550561
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
[TBL] [Abstract][Full Text] [Related]
12. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
[TBL] [Abstract][Full Text] [Related]
13. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
14. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
[TBL] [Abstract][Full Text] [Related]
16. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy.
Ng R; Loreto M; Lee R; Leighl NB
Lung Cancer; 2008 Aug; 61(2):262-5. PubMed ID: 18358559
[TBL] [Abstract][Full Text] [Related]
17. Gefitinib for the treatment of non-small-cell lung cancer.
Hida T; Ogawa S; Park JC; Park JY; Shimizu J; Horio Y; Yoshida K
Expert Rev Anticancer Ther; 2009 Jan; 9(1):17-35. PubMed ID: 19105704
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).
Tiseo M; Bartolotti M; Gelsomino F; Bordi P
Drug Des Devel Ther; 2010 May; 4():81-98. PubMed ID: 20531963
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
